ICO Therapeutics Inc (ICOTF) is focused on innovating drug delivery methodologies to reformulate approved and emerging therapies for broader applications and extended patent protection. Rather than prioritizing research, the company's strategy revolves around prioritizing development, with a focus on securing rights to off-patent, approved, or nearly commercialized medications. These drugs are then improved through redosing or reformulating for new or expanded uses, often incorporating drug delivery technologies such as sustained-release or biodegradable matrices to extend patent life.
Established in 2005, ICO Therapeutics operates in the Biotechnology, Health Care, Health and Wellness, and Pharmaceutical industries. The latest investment of $2.06M in post-IPO equity was made on 19 August 2019.
